Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Darolutamide in mHSPC
NCT06177015Phase 3Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Radiographic Progression Free Survival at 36 months and Overall Survival at 36 months. Started Dec 2023; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06177015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177015.